FAQ on Clene's Updates to ACT-EAP for CNM-Au8(R) Compassionate Use in ALS
Summary
What is the ACT-EAP for CNM-Au8(R) compassionate use in ALS?
The ACT-EAP is an NIH-funded Accelerating Access to Critical Therapies Expanded Access Program for CNM-Au8(R) compassionate use in ALS, aimed at providing treatment to patients with this fatal neurodegenerative disease.
Why is the expansion of the ACT-EAP significant?
The expansion is significant because ALS has no known cure, making accessible treatment programs crucial for patients. Clene has optimized its processes to accommodate up to 180 participants.
How does the ACT-EAP work?
The ACT-EAP is a collaboration among Clene, Columbia University, and Synapticure, funded by the ACT for ALS Act, to provide CNM-Au8(R) to ALS patients through compassionate use.
Who is involved in the ACT-EAP?
Clene, Columbia University, and Synapticure are involved in the ACT-EAP, which was funded by the Accelerating Access to Critical Therapies for ALS Act signed into law in December 2021.
When was the ACT for ALS Act signed into law?
The ACT for ALS Act was signed into law by Congress and President Biden in December 2021.
Where can I find more information about Clene and the ACT-EAP?
More information can be found in Clene’s newsroom at https://ibn.fm/CLNN and on the InvestorBrandNetwork website at https://www.InvestorBrandNetwork.com.
What are the implications of the ACT-EAP for ALS patients?
The ACT-EAP provides ALS patients with access to CNM-Au8(R) through compassionate use, offering hope for treatment where there is currently no cure.
How can I contact Clene for more information?
For more information, you can contact IBN (InvestorBrandNetwork) at Editor@InvestorBrandNetwork.com or visit their website at https://www.InvestorBrandNetwork.com.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 129626